1. DOACs and Urgent Bleeding

3. Overview

4. Management of DOAC Bleeding In the Absence of Reversal Agents

5. Pharmacokinetics of DOACs

6. US Indications and Dosage

7. Bleeding With DOACs

8. Less Harm With DOACs -- Bleed Prevention

9. DOACs Bleeding Events Systematic Review and Meta-Analysis

10. Outcomes of Patients With Major Bleeding Dabigatran vs Warfarin

11. Candidates for Reversal Agents

12. Prior to Reversal Factors to Consider

13. Reversal Agents

14. Idarucizumab

15. RE-VERSE AD

16. Andexanet Alfa

17. Andexanet Alfa: Recombinant, Modified Version of Human FXa Produced in CHO Cells

18. ANNEXA-4 Inclusion/Exclusion Criteria

19. ANNEXA-4 Results

20. ANNEXA-4 Interim Analysis

21. ANNEXA-4 Interim Analysis (cont)

22. Change in Anti-FXa Activity (ng/mL) in Subjects Anticoagulated with Apixaban

23. Change in Anti-FXa Activity (ng/mL) in Subjects Anticoagulated With Rivaroxaban

24. The Bleeding Has Stopped -- What's Next?

25. Reversal Agents Practical Considerations

26. Supply and Distribution

27. Summary

28. Abbreviations

29. Abbreviations (cont)